Just had an interesting thought about Amazon's long-term AI positioning. Most people focus on AWS when they think about Amazon's AI exposure, but here's what they're missing: the company dropped $4 billion into Anthropic, and that move is quietly reshaping how people think about the AI landscape.

Anthropic's Claude 3.5 Sonnet is genuinely impressive. I've been following this closely, and while OpenAI's GPT-4o had its moment, Claude 3.5 came back strong with some serious performance jumps. The Artifacts feature alone is wild - you can literally build websites and run code in a side window. Anyway, I decided to test Claude's stock-picking abilities and asked it what stocks could turn 1K into 1M by 2030. Here's what came back.

First up: Recursion Pharmaceuticals (RXRX). This is an AI-enabled drug discovery company that's actually using tech to shake up how medicines get developed. The industrialized approach they're taking is different from traditional biotech. Even Nvidia threw $50 million at them, which tells you something. The catch? Like most pre-revenue biotech plays, they're burning cash hard. If AI enthusiasm cools, this could take a real hit. That said, watching their Phase 2 readouts in Q3 and Q4 could be telling. High risk, high reward situation.

Then there's Lilium (LILM). They're building electric vertical takeoff aircraft for regional air mobility. Analysts are projecting they could hit 5 billion in revenue by 2032 if eVTOL actually takes off mainstream. They've got 215 million in cash, which should keep them going through commercialization. But here's the reality: the whole eVTOL sector is still unproven. This is pure speculation territory.

Last one is Beam Therapeutics (BEAM). They're developing precision genetic medicines through base editing. Sounds cutting-edge, but the numbers are rough. Revenue dropped 69 percent to just 7.4 million, and they're posting 1.21 loss per share. They've got 1.1 billion in cash to burn through operations until 2027, but I'm not convinced that's enough runway. Gene editing needs to actually deliver for this to work. Honestly, if you're betting on this space, CRISPR Therapeutics feels like the better play.

Look, all three of these are high-risk bets. Claude picked them based on their long-term potential, but the operative word here is "if." If Recursion's pipeline works. If Lilium's aircraft actually commercializes. If Beam's genetic therapies prove viable. The Amazon angle here is interesting though - when you look at how Amazon's backing Anthropic and Nvidia's investing in these biotech plays, you start seeing how AI is reshaping sectors way beyond software. Whether these specific stocks hit that 1M by 2030 target is another story entirely. Only put in what you can afford to lose.